- Home
- SD vs AURA Comparison
SD vs AURA Comparison
Compare SD & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- AURA
- Stock Information
- Founded
- SD 2006
- AURA 2007
- Country
- SD United States
- AURA United States
- Employees
- SD N/A
- AURA N/A
- Industry
- SD Oil & Gas Production
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- AURA Health Care
- Exchange
- SD Nasdaq
- AURA Nasdaq
- Market Cap
- SD 429.3M
- AURA 396.8M
- IPO Year
- SD 2007
- AURA 2021
- Fundamental
- Price
- SD $11.73
- AURA $6.10
- Analyst Decision
- SD
- AURA Strong Buy
- Analyst Count
- SD 0
- AURA 7
- Target Price
- SD N/A
- AURA $22.29
- AVG Volume (30 Days)
- SD 249.4K
- AURA 172.4K
- Earning Date
- SD 11-05-2025
- AURA 11-11-2025
- Dividend Yield
- SD 4.08%
- AURA N/A
- EPS Growth
- SD 86.17
- AURA N/A
- EPS
- SD 2.03
- AURA N/A
- Revenue
- SD $146,165,000.00
- AURA N/A
- Revenue This Year
- SD $30.71
- AURA N/A
- Revenue Next Year
- SD $10.06
- AURA N/A
- P/E Ratio
- SD $5.79
- AURA N/A
- Revenue Growth
- SD 13.89
- AURA N/A
- 52 Week Low
- SD $8.81
- AURA $4.35
- 52 Week High
- SD $13.19
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- SD 57.03
- AURA 41.43
- Support Level
- SD $11.33
- AURA $5.89
- Resistance Level
- SD $11.65
- AURA $6.52
- Average True Range (ATR)
- SD 0.28
- AURA 0.31
- MACD
- SD -0.03
- AURA -0.03
- Stochastic Oscillator
- SD 48.48
- AURA 25.27
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.